Antibody Drug Therapy
Showing 1 - 25 of >10,000
Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant
Not yet recruiting
- Multiple Cancer
- Colorectal Cancer
- MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
- All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
- (no location specified)
Aug 20, 2023
Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection Trial run by the National Institute of Allergy and Infectious Diseases
Not yet recruiting
- Multi-Drug Resistant Hiv-1 Infection
- HIV-1 Infection
- UB-421
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Esophageal Squamous Cell Carcinoma Trial in Shanghai (Tirelizumab, Nab paclitaxel, Carboplatin)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Tirelizumab
- +3 more
-
Shanghai, Shanghai, ChinaRuijin hospital, Shanghai jiaotong university school of medicine
Nov 6, 2023
Patients Suffering From Rare Genodermatoses
Recruiting
- Rare Diseases
- If a targetable cytokine is increased in the lesional skin of a patient, this patient is treated with the respective antibody therapy (off-label use of approved drug).
-
Linz, AustriaKepler University Hospital Linz
Jan 9, 2023
Methamphetamine-dependence, Methamphetamine Abuse Trial in Anaheim, Salt Lake City (Placebo, IXT-m200)
Completed
- Methamphetamine-dependence
- Methamphetamine Abuse
- Placebo
- IXT-m200
-
Anaheim, California
- +1 more
Feb 11, 2022
Multiple Myeloma Trial (Elranatamab (PF-06863135))
Temporarily not available
- Multiple Myeloma
- Elranatamab (PF-06863135)
- (no location specified)
Jul 15, 2022
Muscle Invasive Bladder Cancer, HER2 Expression, Radiotherapy Trial in Shanghai (Disitamab Vedotin and Toripalimab)
Recruiting
- Muscle Invasive Bladder Cancer
- +4 more
- Disitamab Vedotin and Toripalimab
-
Shanghai, Shanghai, ChinaRenji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Jul 31, 2023
Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 Trial in Seattle
Recruiting
- Muscle Invasive Bladder Carcinoma
- +2 more
- Lymphadenectomy
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 9, 2023
DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +6 more
- Axicabtagene Ciloleucel
- +10 more
- (no location specified)
Jan 13, 2023
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial (procedure, drug, biological, radiation, other)
Not yet recruiting
- Recurrent Classic Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma
- Autologous Hematopoietic Stem Cell Transplantation
- +13 more
- (no location specified)
Feb 2, 2023
Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine Trial run by the National Cancer Institute (NCI)
Not yet recruiting
- Neuroendocrine Carcinomas
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Sep 22, 2023
Bevacizumab Combined With PD-1 Monoclonal Antibody in
Not yet recruiting
- Colorectal Cancer
- Bevacizumab Combined With PD-1 Monoclonal Antibody
- (no location specified)
Nov 8, 2023
Light Chain (AL) Amyloidosis Trial (STI-6129)
Not yet recruiting
- Light Chain (AL) Amyloidosis
- STI-6129
- (no location specified)
Jan 11, 2023
Anti CT-P13 Antibody in Moderate to Severe Inflammatory Bowel
Completed
- Inflammatory Bowel Disease
- +2 more
-
Daegu, Korea, Republic ofKyungpook National University Hospital
Feb 15, 2021
Reporting of Antibody-Drug Conjugate Associated Sepsis-related
Completed
- Sepsis (SMQ)
- +2 more
- Antibody-Drug Conjugate
- Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
-
Changsha, Hunan, ChinaCentral South University
Jun 19, 2022
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large
Recruiting
- Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- +3 more
- Brentuximab Vedotin
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Feb 10, 2022
PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus Trial in Beijing (L-DEP and PD-1 antibody)
Not yet recruiting
- PD-1 Antibody
- +3 more
- L-DEP and PD-1 antibody
-
Beijing, Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Mar 8, 2023
Breast Cancer Trial in Shanghai (SHR-A1811, TROP2 ADC)
Active, not recruiting
- Breast Cancer
- SHR-A1811
- TROP2 ADC
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 11, 2023
Rectal Cancer Trial (Short-course radiotherapy combined with furoquintinib and PD-1 mAb)
Not yet recruiting
- Rectal Cancer
- Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
- (no location specified)
Aug 29, 2023
Unresectable Intrahepatic Cholangiocarcinoma Trial (Camrelizumab, Gemcitabine Injection, Cisplatin injection)
Not yet recruiting
- Unresectable Intrahepatic Cholangiocarcinoma
- Camrelizumab
- +4 more
- (no location specified)
Feb 17, 2023
MSS, Rectal Cancer Trial (Sintilimab with Interleukin-2)
Not yet recruiting
- MSS
- Rectal Cancer
- Sintilimab with Interleukin-2
- (no location specified)
Nov 1, 2023
Drug Antibody and Precision Transfusion in China
Recruiting
- Drug-specific Antibodies
-
Guangzhou, Gaungdong, ChinaNanfang hospital of southern medical university
Nov 2, 2022